SmartPill Capsule Clinical Trials are Underway at the University of Kansas Medical Center
The SmartPill Corporation, developer of the SmartPill Capsule, an ingestible medical device that captures biomedical data from within a patients GI tract, today announced that significant progress is being achieved in on-going clinical trials of its SmartPill ACT-I Capsule and GI Monitoring System, and that clinical testing of its innovative product has begun at the University of Kansas Medical Center in Kansas City, Kansas.
Buffalo, NY (PRWEB) July 21, 2005 --- The SmartPill Corporation (www.smartpillcorp.com), developer of the SmartPill Capsule, an ingestible medical device that captures biomedical data from within a patients GI tract, today announced that significant progress is being achieved in on-going clinical trials of its SmartPill ACT-I Capsule and GI Monitoring System, and that clinical testing of its innovative product has begun at the University of Kansas Medical Center in Kansas City, Kansas.
A total of 20 subjects, 10 Normals and 10 Gastroparetics, are expected to participate in the University of Kansas clinical research study. Richard W. McCallum, M.D., Professor of Medicine, and Director of the Center for Gastrointestinal Nerve and Muscle Function at the University of Kansas Medical Center (KUMC), University of Kansas, is the principal investigator. As with the other fives sites participating in SmartPill clinical trials, the primary objective of the KUMC study is to demonstrate the correlation of gastric residence times measured by the SmartPill ACT-I Capsule and conventional gastric emptying scintigraphy.
David Barthel, president and CEO of The SmartPill Corporation, said, The progress we and our partners are achieving is most impressive. Five internationally recognized GI motility centers are participating in the trial, soon to be seven, and we are well on our way toward achieving our objective of testing more than 130 subjects. To date, nearly 60 subjects have participated in the trial and the preliminary indications are extremely encouraging. I am also very pleased that the University of Kansas Medical Center and noted Gastroenterologist and researcher Dr. Richard McCallum have agreed to support our efforts. Dr. McCallum is a leader in the GI motility field, and he and his team are expected to drive testing of Gastroparetics."
The University of Kansas Medical Center study is expected to run 6 - 8 weeks, paralleling clinical trials underway at Massachusetts General Hospital (Boston, MA), Temple University Hospital (Philadelphia, PA), Wake Forest (Winston-Salem, NC), University at Buffalo (Buffalo, NY), and the University of Louisville (Louisville, KY).
About the University of Kansas Medical Center
The University of Kansas Medical Center (KUMC) is a major public research and teaching institution that operates through a diverse, multicampus system. KUMC's many parts are bound together by a mission to serve as a center for learning, research, scholarship and creative endeavor" in the state of Kansas, the nation and the world. For more information, see www.kumc.edu.
About The SmartPill Corporation
The SmartPill Corporation is the developer of the SmartPill ACT-I Capsule and SmartPill GI Monitoring System that will non-invasively aid in the definition, diagnosis, and therapeutic intervention of GI motility disorders; present a more comfortable and convenient alternative to invasive GI diagnostic procedures; and reduce the cost of exploratory GI examinations. Learn more at www.smartpillcorp.com or call The SmartPill Corporation at 800.644.4162.
# # #
|
